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Abstract
Background: A pattern of major and minor congenital anomalies, facial dysmorphic features, and
neurodevelopmental difficulties, including cognitive and social impairments has been reported in some children
exposed to sodium valproate (VPA) during pregnancy. Recognition of the increased risks of in utero exposure to
VPA for congenital malformations, and for the neurodevelopmental effects in particular, has taken many years but
these are now acknowledged following the publication of the outcomes of several prospective studies and
registries. As with other teratogens, exposure to VPA can have variable effects, ranging from a characteristic pattern
of major malformations and significant intellectual disability to the other end of the continuum, characterised by
facial dysmorphism which is often difficult to discern and a more moderate effect on neurodevelopment and
general health. It has become clear that some individuals with FVSD have complex needs requiring multidisciplinary
care but information regarding management is currently lacking in the medical literature.
Methods: An expert group was convened by ERN-ITHACA, the European Reference Network for Congenital
Malformations and Intellectual Disability comprised of professionals involved in the care of individuals with FVSD
and with patient representation. Review of published and unpublished literature concerning management of FVSD
was undertaken and the level of evidence from these sources graded. Management recommendations were made
based on strength of evidence and consensus expert opinion, in the setting of an expert consensus meeting. These
were then refined using an iterative process and wider consultation.
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Results: Whilst there was strong evidence regarding the increase in risk for major congenital malformations and
neurodevelopmental difficulties there was a lack of high level evidence in other areas and in particular in terms of
optimal clinical management.. The expert consensus approach facilitated the formulation of management
recommendations, based on literature evidence and best practice. The outcome of the review and group
discussions leads us to propose the term Fetal Valproate Spectrum Disorder (FVSD) as we feel this better
encompasses the broad range of effects seen following VPA exposure in utero.
Conclusion: The expert consensus approach can be used to define the best available clinical guidance for the
diagnosis and management of rare disorders such as FVSD. FVSD can have medical, developmental and
neuropsychological impacts with life-long consequences and affected individuals benefit from the input of a
number of different health professionals.
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Introduction and objectives to the consensus
statement
Sodium valproate (VPA) is an effective antiepileptic drug
(AED) which is also used to treat bipolar disorder, mi-
graine and other mental health problems. It was first li-
censed for use in Europe in the mid 1970’s. In February
2018 the Pharmacovigilance Committee of the European
Medicines Agency recommended that VPA should not
be used in pregnancy unless the women concerned had
seizures which were unresponsive to other drugs [1]. In
April 2018, the Pharmacovigilance Committee of the
European Medicines Agency recommended that women
using VPA should use effective contraception and agreed
that VPA use during pregnancy should be restricted to
women with epilepsy who are unresponsive to other
drugs [2]. In the forty years from when VPA use began
in Europe, many women took this drug during preg-
nancy as it is an effective AED, often providing better
seizure control than other AEDs [3]. From the early
1980’s reports began to be published suggesting that
VPA exposure during pregnancy was associated with an
increased risk for congenital malformations and poorer
developmental trajectories [4–12]. As most of these were
initially anecdotal, it was not until results became avail-
able from long term prospective cohort studies of chil-
dren born to mothers taking VPA and from pregnancy
registers [13–18], that the serious teratogenic effects of
VPA were appropriately acknowledged. Currently avail-
able evidence suggests that the risk of congenital malfor-
mation after VPA exposure is around 11% [19, 20] but
that the level of risk is associated with dose, with the risk
being as high as 24% when the dose is over 1500 mg
daily [20]. The risks to neurodevelopment appear diverse
and depend on the specific domain (e.g. of cognition or
behaviour) under study. There is replicated evidence of a
reduction in IQ of 8–10 points compared to unexposed
individuals and specific deficits in verbal skills [21, 22]
as well as language impairment and poorer levels of daily
living skills [23]. The prevalence of autism spectrum dis-
order (ASD) is 6–15% in VPA exposed individuals [24–
26] which is greatly increased compared to the back-
ground population risk. In addition, a number of medical
symptoms have been reported at increased frequency in
valproate exposed individuals [27]. All of these features
may combine to give a complex picture which requires
multidisciplinary management requiring a large number
of different professionals. Though we expect the number
of individuals with valproate related difficulties to decline
in future years due to changes in prescribing [28], there
are still many children and adults living within Europe
with the consequences of prenatal exposure to VPA. The
number of affected children across the spectrum within
the UK, for example, is estimated to be in excess of
20,000, based on the number of women prescribed VPA
in pregnancy and the percentage of those estimated to
show symptoms as a result, but no firm number is cur-
rently known. However, despite widespread use of VPA to
treat epilepsy and bipolar disorder for a few decades the
number of exposed children when viewed at a population
level is likely to be relatively small, meaning that clinicians
will have limited experience with the condition. Correct
diagnosis and specialist management of this cohort is
therefore important.
The objectives of this consensus statement are to pro-
vide guidance on the most effective management of the
medical and neurodevelopmental problems of individ-
uals demonstrating the effects of prenatal exposure to
VPA from infancy to adulthood. This is undertaken in
order to minimise health complications, to optimise the
chances for individuals to achieve developmentally ac-
cording to their potential, to enhance social adaptation,
and to clarify the clinical diagnostic criteria for a dis-
order for which there remains no specific laboratory
diagnostic test or biomarker. Whilst previous literature
has referred to the effects of VPA exposure in utero as
Fetal Valproate Syndrome [6, 10] we propose and use
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the term Fetal Valproate Spectrum Disorder (FVSD) to
refer to the range of clinical and developmental effects at-
tributed to exposure to VPA in utero. Further explanation
of the use of this new term is given in the section on Diag-
nosis of Fetal Valproate Spectrum Disorder below.
This consensus statement was drawn up as an initiative
of the European Reference Network, (ERN) ERN-ITHACA.
The network encompasses several EU countries, with dif-
fering provision for healthcare, therapies and educational
needs for individuals with developmental disorders. ERNs
were established in 2017 as part of the EU Cross Border
Health Care Directive after the responses to a survey of the
needs of rare disease patients across Europe were taken into
account [29]. We aimed for EU-wide coverage of this topic
area when drawing up our recommendations so in some
areas we have needed to be less specific and more general
in our recommendations as a result. Our aim is that
country-specific notes should be added to any future trans-
lations of this document.
Target groups and questions to be covered
This document is intended for all health professionals in-
cluding paediatricians, specialist paediatricians (e.g. neph-
rology, cardiology etc.) adult physicians and primary care
physicians looking after the medical aspects of individuals
with FVSD, for professionals involved in the diagnosis of
FVSD and for those involved in management of the neu-
rodevelopmental aspects of FVSD, including community
paediatricians, educational psychologists, clinical psychol-
ogists, child psychiatrists and educators. It will also pro-
vide relevant information for professionals involved with
managing the social aspects of the condition, (e.g. parents,
social workers, support workers and occupational health
physicians). The questions addressed by the group are
listed in Table 1.
Methodology for producing the expert consensus
document
The overall process is outlined in Fig. 1. Peer-reviewed
publications were ascertained by searching the PubMed
and Cochrane databases. The search terms Fetal/Foetal
and/or Valproate and/or Syndrome were combined with
the terms management, diagnosis, growth, treatment,
neural tube, skeletal, joint, limb, cardiac, gastrointestinal,
feeding, genitourinary, renal, eye, ear, development, in-
tellectual disability, medical, neurodevelopment, cogni-
tive impairment, neuropsychology, autism spectrum,
behaviour, neonatal, adult. We searched all articles from
1970 to 2017 but confined ourselves to papers published
in English. A check for further relevant peer-reviewed
articles was made by reviewing those ascertained by the
French PNDS (National Protocol for Diagnosis and
Care) document published in 2017 [30]. This document
was compiled following the search recommendations of
the Haute Autorité de Santé [31]. We did not identify
any additional articles through this process but we trans-
lated the PNDS document into English and, after asses-
sing the recommendations contained therein using the
AGREE II tool [32] against which they compared
favourably, the translated document was used as an add-
itional resource for our working group. We also assessed
information from meeting abstracts, from our own un-
published data, and from reviews and book chapters on
the topic known to members of the expert group be-
cause of their interest in the field over a long period of
time. We compiled a table of all of the individual case
reports of individuals with congenital malformations
after VPA exposure in the literature. We considered the
strengths and limitations of the body of evidence ob-
tained; there have been no randomised controlled trials
(RCTs) carried out in this area because once adverse ef-
fects due to VPA had been reported, RCTs of pregnancy
exposure were considered unethical. In human teratol-
ogy research the gold standard is rigorous prospective
observational studies with adequate controls over likely
confounding variables. There have been reservations
about accepting the results of some studies in this area
because of poor study design including small study num-
bers, lack of blinding of assessors, presence of many
confounding factors and biased ascertainment [33]. For-
tunately, although we needed to rely on lower levels of
evidence for some recommendations, there have been
several large prospectively ascertained studies of con-
genital malformations and neurodevelopment in this
area which have replicated findings from the poorer
quality studies. The findings from pregnancy registers,
though subject to some bias if registers were based on
self-selection, was also a source of information which
contributed greatly to our understanding in this area
[34]. Overall we felt fairly confident about total evidence
Table 1 Questions Addressed By the Consensus Group
1 What are the diagnostic criteria for Fetal Valproate Spectrum Disorder
(FVSD)?
2 What investigations should be carried out in individuals with FVSD?
3 Are there any specific therapies which benefit individuals with FVSD?
4 What health and developmental surveillance should be undertaken
in individuals with FVSD and by whom?
5 What neuropsychological assessments are needed for individuals
with FVSD?
6 What school adjustments may be beneficial for children with FVSD?
7 What transition arrangements should be made for individuals with
FVSD?
8 What medical checks should adults with FVSD have and who should
undertake these?
9 What is the best format for the recommendations from the expert
consensus group?
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from these diverse sources, as many of the findings were
replicated across studies. There has been very little data
on medical follow-up and health surveillance in this
population [35]. Much of the information available in
this area has been driven by lay support groups [27].
The anecdotal case report data was considered fairly
weak, as many cases were reported many years ago, be-
fore the advent of tests which could exclude genetic dis-
orders, and some cases were exposed to polytherapy or
were subject to other confounders. One relevant point is
that the working group which was convened included a
diverse range of professionals (Clinical Geneticists, Pae-
diatricians, Teratologists, Neonatologists, Clinical Psy-
chologists, Child Psychiatrists, Paediatric Surgeons and
others) who had a wealth of professional experience in
the diagnosis and management of the health and clinical
follow up of individuals with FVSD. That said, in light of
the lack of systematic evidence pertaining to health and
clinical follow up, consideration of this area is likely sub-
ject to certain biases.
The articles were initially reviewed by JCS, RB and MR
and from these 8 core articles [6, 10, 12, 19, 22, 27, 36, 37]
were selected based on a) the level of evidence they pro-
vided ranging from 1 metanalyses/systematic reviews or
RCTs with low risk of bias, through to 4, expert opinion,
b) the size and design of the studies c) their relevance to
diagnosis and management of FVSD. Where possible, pa-
pers with obvious bias (small studies, retrospective studies,
un-blinded studies, ascertainment of participants from
biased groups) were avoided, but due to the lack of papers
with a high level of evidence for certain aspects of the
condition, and the fact that we were interested particularly
in aspects of clinical management (which is under
researched), we decided to include some retrospective co-
hort studies if they were larger or provided information
about aspects of FVSD not otherwise documented else-
where. We took into account the bias that inclusion of
these papers might introduce. The core papers selected in-
cluded two Cochrane reviews on congenital malforma-
tions and neurodevelopment [19, 22]. The eight core
articles, together with the translated PNDS document
[30], the list of congenital malformations from case re-
ports referred to above and a paper unpublished at the
time but now in print, documenting the cognitive and
neurodevelopmental profile in Fetal Valproate Syndrome
[37] were graded for level of evidence and sent to each ex-
pert in the group for review. In addition, for each of the
areas (e.g. cardiology, ophthalmology, neurodevelopment),
the expert was also provided with all available specific pa-
pers pertaining to his/her topic. We asked each member
to make management recommendations based on the evi-
dence provided, and to provide further evidence and refer-
ences from their own field if additional recommendations,
not covered in the literature provided, were considered
necessary. We sought opinions from experts covering a
broad number of different areas consistent with the symp-
tomatology of FVSD, and also included a parent expert
from a National Support Group within our consensus
group. Each expert was requested to enter their recom-
mendations into an Excel spreadsheet and these were then
Fig. 1 Outline Of The Process Of Producing The Consensus Statement
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collated and discussed at an expert consensus meeting
held in Manchester in March 2018. Where experts could
not attend, they were asked to provide the Excel summary
sheet and the rationale for their recommendations which
were presented on their behalf. One participant (CD) did
not complete the summary sheet but read the background
literature and made recommendations which were re-
corded by JCS at a face to face discussion and presented at
the consensus meeting.
The day long consensus meeting was attended by 16
members of the consensus group. The proposed recom-
mendations were presented and debated. During the dis-
cussion we also debated additional sources of data
known to individual experts. We made use, for example,
of unpublished data from follow-up to age 6 of a pro-
spective cohort of UK children in Liverpool and Man-
chester exposed to antiepileptic drugs in pregnancy in
whom physical examinations and measurement of
growth parameters had been undertaken at age three
and 6 years, classing it as lower level evidence in the
light of the fact that it remains unpublished. Where
there were differences of opinion these were debated
and draft recommendations re-worded until they were
acceptable to the majority of the group. When making
recommendations we took into account the applicability
of the available published evidence to the population we
were targeting, how consistent the body of evidence was,
how feasible it would be to tailor the recommendations
to health and education systems across different coun-
tries, and the balance of benefits and harms of the rec-
ommendations made.
Following the expert consensus meeting a draft list of
all of the recommendations was drawn up and circulated
to members of the group who were asked to score these.
Table 2 outlines the process for scoring the recommen-
dations. Members were asked to indicate whether they
agreed or disagreed with the recommendation and, if
disagreeing, to state the reason. They were allowed to
abstain from scoring the recommendation if it was out-
side their area of expertise. They were also asked to
comment as to whether the recommendation was, in
their opinion, based on evidence and/or consensus
agreement, or covered an area where there was agreed
best practice. Recommendations scored as C after this
process were discarded or re-worded and re-scored until
acceptable as A or B. Only recommendations scoring A
or B were ultimately kept.
After collating the scores, a first draft of the consensus
statement was circulated to all members of the expert
group. It was revised based on their feedback and then
circulated to a broader group of experts and patients/
parents with experience of diagnosis and management of
FVSD for review and comment. This group included
clinical geneticists from within the European Reference
Network for Congenital Malformations and Intellectual
Disability, ERN ITHACA. We also sought comments
from the ERN e-PAG group (European Patient Advocacy
Group) and relevant lay support groups. Evaluators were
asked if they would read and comment on the draft and
feedback on the general content, and the recommenda-
tions in their specific area, using a structured proforma
which included questions on the language used, length
and format as well as a specific request to comment on
recommendations made in their field of practice and a
free text box. They were requested to complete this task
within 2 weeks. The consensus document was revised
and following this process and a final version agreed. As
supplementary information to the overview document, it
had been agreed at the consensus meeting to include a
number of shorter summary sheets summarising the im-
portant recommendations which are relevant to different
professionals and to parents. These included a summary
sheet for patients and families, one for paediatricians,
one for family doctors caring for an adult with FVSD,
one for educators and one for psychologists. These are
included here as Additional files 1, 2, 3, 4 and 5.
Including experts with varying areas of expertise and
from different countries, along with parent and lay
group representation, enriched the process of care plan
development and was also an educational process for
those involved in the working group. Outlining the
methodology of the process and the requirements from
the individual experts together with provision of the
overview key references to all members, clear instruction
on grading of evidence and recommendations, and the
availability of administrative help from a coordinator, fa-
cilitated the engagement of experts and improved the
ease and quality of the process.
Recommendations
In making these recommendations we have tried to be as
explicit as possible. However, due to the lack of a body of
evidence uncertainty remains in some areas and specificity
was not always possible. For each recommendation we
Table 2 Process For Agreeing and Scoring Recommendations
Agreement Score
+++ > 75% agree with the recommendation
++ 50–74% agree with the recommendation
+ 25–49% agree with the recommendation
– < 25% agree with recommendation
Evidence Score
A Based on evidence +/− expert consensus
B Based only on consensus agreement and/or best practice
C No evidence or consensus agreement/not currently specified as
best practice
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have stated 1) the recommendation, 2) to whom/the tim-
ing at which it applies, 3) the rationale for the recommen-
dation, 4) the consensus score, 5) the level of evidence
and 6) any relevant references. Where there were different
options we have made this clear. We have summarised
key information contributing to these decisions in the text.
We have taken the key recommendations as they apply to
our different target groups and formulated these into
one-page summary sheets for the relevant professionals
and for parents, included here as an additional file.
Comment on measures to avoid valproate exposure in
pregnancy
The group considered it important to include in this
consensus statement the current guidance which has re-
cently been put in place to ensure avoidance of VPA ex-
posure during pregnancy. The European Medicines
Agency (EMA) last issued guidance on the 23rd April
2018 [2] and this is summarised in Table 3.
Diagnosis of Fetal Valproate Spectrum Disorder (FVSD)
Bjerkedal et al. [38], who reported the results of an epi-
demiological study in the Rhône-Alpes region of France
in 1982, were the first to draw attention to the increased
risk of spina bifida after VPA exposure in pregnancy. Re-
ports of other malformations followed, and in 1984 the
first series of seven children affected by the Fetal Valpro-
ate Syndrome (FVS) was published by Di Liberti et al.
[6] Further reports characterised FVS as a consistent
pattern of major and minor malformations, facial dys-
morphism and impaired development [8, 10, 12, 36, 39,
40]. Risks are increased in particular for neural tube de-
fects [7, 13], congenital heart disease, cleft palate [41],
radial ray defects [42–46], ophthalmological [47–49] and
genitourinary anomalies [6, 50–52]. Associated minor
anomalies include inguinal hernia [53], overlapping toes
[12] and scalp defects [6, 54]. The facial dysmorphism is
characterised by a broad nasal bridge, short nose with
forward-facing (anteverted) nostrils, small mouth with
thin upper lip, everted lower lip flat philtrum, ridging of
the metopic suture and neatly arched eyebrows [6, 9, 10,
12, 51, 53, 55]. Problems with impaired cognition and
neurodevelopment, including an increased risk for atten-
tion deficit hyperactivity disorder (ADHD) and autism
spectrum disorder (ASD), went unrecognised initially
but are now proven to be part of the FVS phenotype
[21, 22, 24–26, 37, 56, 57].
The fact that the prevalence of the cognitive and
neuropsychological deficits after VPA exposure is higher
than that of the prevalence of VPA associated malforma-
tions suggests that an individual can demonstrate ad-
verse effects of VPA exposure without necessarily having
all of the physical features seen in FVS. In fact, impair-
ment of functioning is known to occur at lower doses
and at increased frequency than structural malforma-
tions across teratogenic exposures [55]. Further, studies
have specifically excluded VPA exposed children with
major congenital malformations and still find the in-
creased risk of both reduced IQ [57, 58] and autistic
spectrum disorder [25]. Kini et al. [59] raised the ques-
tion of whether it was possible to have impaired devel-
opment as a result of VPA exposure in the absence of
dysmorphic facial features. The dysmorphic features as-
sociated with VPA exposure can be subtle and age
dependent and designating individuals as having the
characteristic dysmorphism or not is difficult, especially
for those with limited expertise in the area. There are
many varied presentations following exposure in utero
to VPA as not every affected individual will have identi-
cal features. Due to these points the expert consensus
group felt that whilst the presence of a typical facial
presentation makes the diagnosis more certain, typical
facial features are not absolutely required to be able to
diagnose that an individual has been affected by expos-
ure to VPA in utero, particularly if the dose of exposure
was low or if the exposure occurred after the period of
fetal facial development. These points provided the ra-
tionale for moving towards using the term Fetal Valpro-
ate Spectrum Disorder, FVSD, a situation akin to that
used when discussing adverse effects of exposure to al-
cohol in utero [60]. This seems appropriate, since chil-
dren with neurodevelopmental effects of VPA exposure,
but without significant malformations, can be as im-
paired in their everyday functioning as children with
classical FVS, and need to be identified in order to be of-
fered the appropriate management.
The diagnosis of FVSD is difficult, as there is no specific
biomarker that can be assayed in this condition to prove
diagnosis, though there are conditions with overlapping
features which need to be excluded [51]. Diagnostic
Table 3 Measures to Avoid VPA Exposure During Pregnancy;
Summary of EMA guidance from the Pharmacovigilance Risk
Assessment Committee
1 VPA must not be used for treatment of migraine or bipolar disorder
during pregnancy
2 VPA must not be used to treat epilepsy during pregnancy unless
there is no other effective treatment available. Women requiring VPA
treatment should be supported and counselled
3 VPA should not be prescribed to any girl or woman able to have
children unless she is on a Pregnancy Prevention Programme. This
will include an assessment of potential to become pregnant,
pregnancy tests before starting and during treatment, counselling
about the risks of VPA treatment and the need for effective
contraception whilst on treatment, review of treatment by a
specialist at least annually and signing of a risk acknowledgement
form
4 Women and girls who have been prescribed valproate should not
stop taking their medicine without consulting their doctor as doing
so could result in harm to themselves or to an unborn child.
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criteria for Fetal Anticonvulsant Syndrome were drawn up
by Dean et al. in 2000 [53] and our expert consensus
group reviewed these prior to developing new criteria for
FVSD which reflect our current knowledge and the now
established evidence base. The revised criteria presented
here in Table 4 have been divided into “essential criteria”,
defined as those which must be present for an FVSD diag-
nosis, “suggestive” features which are seen at significantly
increased frequency (> 10%) in FVSD, and “supportive”
features which occur independently within the general
population but are more common in FVSD. The support-
ive criteria are weighted according to their frequency in
the general population (the more common they are in the
general population the less weight they are given).
Dysmorphic facial features have previously been consid-
ered as a strong diagnostic handle for FVSD [59] as these
appear specific to the condition. Figure 2 demonstrates the
classical facial features, which change over time but are still
recognisable in adults. In view of the fact that they may be
difficult to recognise in their milder form by those who are
not expert in the area, and that there is debate as to whether
their presence is required, they have been listed as “suggest-
ive” rather than “essential” criteria. Figure 3 shows limb mal-
formations which are associated with valproate exposure.
Given the prominence of the cognitive, social and motor
difficulties within the presentation of FVSD, individuals
with the condition should be referred to a clinical psych-
ologist or neuropsychologist as part of the diagnostic
process for objective assessment of cognitive and neuro-
psychological problems unless the child clearly has a se-
vere neurodevelopmental impairment in which case the
presence of this will be clear. The focus of the assessments
will vary by age but should cover cognitive, speech and
motor development in infancy and IQ, language, memory,
attention and executive functioning at school age or older.
Management of Fetal Valproate Spectrum
Disorder
In view of the fact that multiple body systems are af-
fected in FVSD the need for a multidisciplinary model of
care was acknowledged and strongly supported by the
group. As the signs and symptoms vary with age we felt
it important to encompass preconception and prenatal
management as well as management of the neonate,
child, and adult. The recommendations for management
have been divided according to the clinical setting and
age at which individuals are seen rather than by body
system, and are listed in Table 5. Where literature evi-
dence is available references are given and papers listed
at the end of the document.
Preconception care and advice
Preconception care in women with epilepsy has recently
been the subject of European debate, with some countries
also issuing their own guidance [61, 82, 83]. In April 2018
the European Medicines Agency endorsed new measures
to avoid valproate exposure in pregnancy [2]. Essentially,
VPA may not be used to treat bipolar disorder or migraine
in pregnancy and can only be used for the treatment of
epilepsy if women are on a pregnancy prevention
programme and sign documentation affirming that a dis-
cussion of the risks has taken place. It is recommended
that folic acid, taken in doses 0.4-5mg daily should be
taken from 2 to 3months before conception and should
be continued until 12 weeks of pregnancy. Recommenda-
tions of the dose vary widely between countries and soci-
eties. The Medicines and Healthcare Regulatory Agency
(MHRA) recently issued specific guidance to all women
for whom VPA is being prescribed [82]. A daily dose of
4-5mg is recommended if there is a family history of
neural tube defect. The evidence of high dose folic acid in
preventing VPA teratogenesis is conflicting [64, 65]. A re-
cent small trial of whole pregnancy folate supplementation
suggested that there are psychological developmental ben-
efits for children [84]. However, current evidence suggests
that after the first trimester, high doses are not recom-
mended or justified [66, 85, 86].
Pregnancy
The risk of congenital malformations in babies exposed to
VPA in pregnancy is of the order of 10–11% but increases
as the dose increases and can be as high as 24% [87]. Some
malformations are specifically increased after VPA expos-
ure. The European Surveillance of Congenital Anomalies
(EUROCAT) antiepileptic study database, gathering data
from several congenital malformation registries [88], sug-
gested a relative risk for neural tube defects of 12.7,
whereas Weston et al. in the Cochrane review on malfor-
mations [19] identified a lower relative risk of around 5.3
from prospective observational studies. The risk of cardiac
malformations is increased 2–3 fold, that for cleft palate
increased five-fold, that for craniosynostosis six-fold, and
that for hypospadias and genitourinary (GU) malforma-
tions five-fold. Limb malformations, more specifically ra-
dial ray defects, are also increased. The effects are dose
related [88]. In view of this increased risk malformations
should be specifically sought on a routine detailed anom-
aly scan at 20 weeks and the fetal medicine specialist or
ultrasonographer carrying out the scan should be made
aware of the history of VPA exposure. However, although
it is possible to visualise many of the structures concerned,
cleft palate and some heart defects may go undetected.
Contrary to early literature, cleft lip is not increased in fre-
quency [41]. Further scans are not necessary if the 20 week
scan is normal. If abnormalities are detected on the fetal
anomaly scan these should be discussed with the parents
and may require follow-up scans. In the event that a
woman becomes pregnant unexpectedly whilst taking
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VPA she should not stop her medication without consult-
ation with her neurologist, as uncontrolled seizures pose a
significant risk to her and possibly, although less clear, the
unborn child. The incidence of intrauterine growth retard-
ation and Caesarean section is not significantly increased
in mothers taking VPA in pregnancy [52]. Where a major
malformation has been identified during pregnancy, and
the pregnancy continues, delivery should be planned to
take place in a hospital with the appropriate facilities for
neonatal care and the neonatal team should be involved
during the pregnancy.
Neonatal period
The majority of infants exposed to VPA during preg-
nancy will have a normal neonatal period [52]. Though
the NEAD study [89] did not find any difference in
Apgar scores across infants exposed to different AED
monotherapy drug types, two studies [90, 91] have found
a near doubling of risk of having a lower Apgar score in
VPA exposed infants in larger cohorts. There have been
some reports of neonatal withdrawal symptoms and
hypoglycaemia. Though Thisted et al. [70] observed
these in 13/22 VPA exposed infants, in a subsequent
Table 4 Diagnostic Criteria For Fetal Valproate Spectrum Disorder. For diagnostic criteria to be met all essential criteria must be
fulfilled in addition to two suggestive criteria or one suggestive plus a supportive score of 3 or more
Grade Criterion Comments
Essential Confirmed exposure to VPA
during pregnancy
Any dose or duration
Essential Has no other recognisable diagnosis
which would explain the phenotype
As evidenced on assessment by a
clinical geneticist or
other professional with relevant
expertise
Essential Normal microarray-CGH and
Fragile X studies
Part of diagnostic work-up
Essential Other teratogenic disorders with
clinical overlap excluded
In particular fetal alcohol syndrome /
spectrum disorder
Suggestive Facial dysmorphism consistent
with VPA exposure
(flat philtrum, thin upper lip, full,
everted lower lip,
short anteverted nose, small mouth,
epicanthic folds, neat arched
eyebrows,
broad nasal root) see Fig. 3
Include review of photographs at a
younger age
and take into account variability of
phenotype
with age (see Fig. 3)
Suggestive Cognitive profile consistent with
current knowledge of that
associated with valproate exposure
a) discordant from parents
b) in infancy: motor and speech delay,
c) school aged: IQ, verbal reasoning,
communication and executive
functioning deficits
Suggestive Presence of social communication
difficulties/autism spectrum disorder
Occurs in 6–15%
Suggestive Spina bifida 20 fold risk
Score
Supportive Congenital cardiac defect Confirmed on echo 2
Suggestive Cleft palate 2
Supportive Metopic suture synostosis 2
Supportive Radial ray defect Includes mild variants with flat
thenar eminences
2
Supportive Genitourinary malformations Hypospadias, abnormal collecting
system, hydronephrosis
2
Supportive Laryngomalacia/stridor 2
Supportive Joint laxity Beighton 6 or more 1
Supportive Talipes requiring surgery 1
Supportive Digital anomalies Overlapping toes, camptodactyly,
clinodactyly
1
Supportive Ophthalmological anomalies Coloboma, strabismus, refractive error 1
Supportive Enuresis/poor bladder control Requiring investigation 1
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prospective study of 227 women with epilepsy (WWE) and
315 control women [52], there was no significant difference
in neonatal problems or admission to the neonatal intensive
care unit between the two groups. In a study from Norway,
in which 215 babies were exposed to VPA, there was no in-
creased incidence of neonatal hypoglycaemia [74]. VPA is
not an enzyme-inducing AED and so the risk of haemor-
rhagic disease of the newborn is not increased unless
mothers are taking other enzyme-inducing medications.
Oral administration of Vitamin K to mothers during preg-
nancy is not specifically needed [63]. In many countries
however, 1mg Vitamin K given intramuscularly is offered
to all infants after birth.
VPA does not pass through into breast milk in large
concentrations [92]. A study by Meador et al. of the IQ
of children exposed to VPA who were breast fed com-
pared to those who were not demonstrated no adverse
effects of breastfeeding and a higher overall IQ for
breastfed infants [93]. A further Norwegian study failed
to demonstrate an adverse impact on neurodevelopment
at 6 and 18months [71]. Whilst further evidence is re-
quired, currently breastfeeding should be encouraged
[72]. A thorough neonatal baby check [67] is essential
after birth because of the higher risk of both major and
minor malformations. Particular effort should be made
to visualise the palate, to check for limb defects, most
common involving the radial rays [42–46], to check the
spine, and to note any dysmorphic facial features (Listed
in Table 4) which are often very recognisable in the neo-
nate. Pronounced ridging of the metopic suture with tri-
gonocephaly [12, 76, 77] may indicate craniosynostosis
which will require a referral to a craniofacial team. The
risk for malformations of the genitourinary (GU) tract
and the heart is increased. Though septal cardiac defects
are more common, in some instances very complex con-
genital heart defects, which may be difficult to detect in
neonates, may be present [94] and so one-off scans of
the renal tract and the heart should be arranged after
birth. Infants exposed to VPA have a significantly in-
creased risk for neural tube defects, most of which will
Fig. 2 Facial Features Associated With Valproate Exposure At Different Ages. Note the presence of anteverted nares, small mouth, thin upper lip,
everted lower lip, flattening of philtrum, prominent midline to forehead. Features are attenuated but still apparent in young adult
Fig. 3 Minor limb malformations Seen After VPA exposure. Note the hypoplastic and overlapping toes and flattening of the arches due to the
joint laxity frequently seen in FVS
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Table 5 Recommendations For The Management Of Fetal Valproate Spectrum Disorder
Recommendation Agree
+++ > 75%
++ 51–74%
+ < 50%
Evidence
Strength
A B C
Diagnosis
Diagnosis should be made by a clinician with expertise in the area based on the stated diagnostic criteria +++ B
Microarray analysis and Fragile X studies should be undertaken and other syndromic diagnoses suggested by
history and clinical findings ruled out [53]
+++ A
The diagnostic process should include a developmental/neuropsychological assessment [53] ++ A
Preconception Counselling
Treatment with VPA should be supervised by a doctor specialising in the area who will offer advice according to
EMA and country-specific guidance [2, 61]
+++ A
Women and girls taking VPA who find themselves pregnant should not stop taking their medication without
consulting their doctor [61]
+++ A
Possible genetic causes for the mother’s seizures should be considered and investigated if appropriate [62] +++ A
Recurrence risks for seizures in a child should be assessed and communicated [62] ++ B
As for all pregnancies, folic acid should be taken from 2 to 3 months before conception and continued until 12
weeks [63]. The dose to be taken varies between countries. After the first trimester doses high doses are not
recommended or justified [64–66]
++ A
Pregnancy and Neonatal Period
In pregnancies where VPA is being taken women should seen in a joint obstetric/neurology clinic [63] ++ B
Ultrasound scans should be carried out at around 13 and 20 weeks depending on country. Additional scans are not
needed if the heart can be visualised adequately at 20 weeks
++ B
The ultrasonographer/radiologist should be made aware of a history of VPA exposure and the type of structural
anomalies which are associated and can be looked for especially on scan
+++ B
If a major fetal malformation is detected on antenatal scans, discussion as to the most appropriate place for
delivery should take place after detection of the anomaly [63]
+++ B
The neonatal check [67] should be carried out by a professional with knowledge of FVSD. Special care should be
taken to visualise the palate directly and to check for submucous cleft palate, to look for radial ray defects, talipes
and ridging of the metopic suture indicating metopic synostosis.
++ B
If spinal dysraphism is suspected clinically e.g. the presence of dermal sinus, a skin dimple which is very large (> 5
mm) or high on the back or if there is ultrasound evidence of a spinal cord anomaly, the child should be referred
to a paediatric neurosurgeon for clinical assessment and further imaging. Small sacral skin dimples/pits can be
safely ignored [68, 69].
+ B
Midwifery/paediatric staff should be alert for signs of hypoglycaemia and blood sugar should be checked if these
occur [70].
+++ B
Breast feeding should be encouraged [71, 72]. Feeding should be established before discharge home +++ A
Airway symptoms should prompt assessment by a suitably experienced airway surgeon [73]. Assessment may
include rigid airway endoscopy under GA to exclude laryngeal abnormalities and tracheomalacia.
+++ B
If signs of drug withdrawal are present these should be treated [70, 74] +++ A
If talipes is present referral should be made to a physiotherapist/or paediatric orthopaedic surgeon as required [75] +++ B
Before discharge, arrangements for follow-up of the baby with a paediatrician and/or other specialists should be
put in place. This professional will be responsible for coordination of health surveillance and care
+++ B
A renal ultrasound should be arranged after birth for all VPA exposed infants [18, 19] +++ A
A one-off cardiac echocardiogram should be arranged [18, 19] +++ B
An epilepsy nurse should see the mother after delivery to review her seizures and medication and discuss childcare
and contraception.
++ B
Paediatric Surveillance: General Points
At all ages, if malformations, medical problems or developmental problems are detected the paediatrician should
refer the child on to the appropriate specialist
+++ B
Height, weight and head size should be measured at each paediatric visit and plotted on the appropriate growth
charts
+++ B
Enquiry about hearing and vision problems should be made at each visit [27, 47] +++ B
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Table 5 Recommendations For The Management Of Fetal Valproate Spectrum Disorder (Continued)
Recommendation Agree
+++ > 75%
++ 51–74%
+ < 50%
Evidence
Strength
A B C
If developmental problems are suspected at any stage referral should be made for a comprehensive developmental
assessment
+++ A
Paediatric Assessment and Health Surveillance of Infants
In addition to the routine health checks by the health visitor, a paediatric appointment should be arranged at the
age of six to eight weeks and further review at 9 months
++ B
A full examination should be carried out in the first year to detect malformations. This should include detailed
examination of the hands and forearms to look for signs of radial ray defect. Minor signs of this may include a
hypoplastic thumb or flat thenar eminence
++ B
Hip stability should be checked and ultrasound scan arranged if any concerns ++ B
Where talipes is resistant to treatment or where there are abnormal neurological signs in the legs imaging of the
spine should be carried out [69, 75]
+++ A
If there are clinical concerns about head shape or growth the child should be promptly referred to a Craniofacial
Unit for evaluation and possible treatment [76, 77]
+++ B
A developmental history should be taken and development should be assessed +++ B
An ophthalmological examination including orthoptic assessment, full ocular examination (to look for iris and
chorioretinal coloboma, cataract and other abnormalities), and cycloplegic refraction should be carried out during
the first 6 months of life [78]
+++ B
Early intervention for hearing loss is indicated to limit impact on development +++ B
Paediatric Surveillance At 18 months
Health and development should be reviewed by a paediatrician or an appropriately trained health professional at
18 months
+++ B
A screen for autism spectrum disorder/social communication disorder should be undertaken by the community
paediatrician
+++ B
Surveillance During Childhood
After the 18month check progress should be reviewed by an appropriate health professional on an annual basis
until school age, with a check being carried out prior to starting school. Thereafter appointments should be
arranged the year before leaving junior school (age 10) and the year before public exams (age 13–14).
++ B
If there are concerns about speech and language a referral for formal assessment by a speech and language
therapist should be made by 2.5 years
++ B
Joint hypermobility should be considered as a cause in those presenting with leg pains and assessed by Beighton
score [79]. If score > 6 referral to a paediatric physio should be made and an age appropriate graded exercise
programme administered to build up core muscle strength and endurance. This might also include swimming and
soft play. Special requirements for joint hypermobility should be included in the individualised educational plan.
+++ B
Offer referral to a physiotherapist for fatigue management and advice on management of joint laxity and posture
where these are prominent features
+++ B
Where there are foot deformities or flat feet referral to a podiatrist for orthotics should be made [80] +++ A
Good posture and spinal strengthening exercises should be recommended ++ B
Enquiry about sleep disordered breathing should be made at each surveillance visit +++ B
Children with impaired hand function should be referred to an occupational therapist +++ B
An ergonomic assessment of the school environment should be undertaken if required by an occupational
therapist to ensure that the environment is suited to any specific needs of the child
++ B
An annual ophthalmic assessment to look for amblyopia, strabismus, refractive error and other abnormalities should
be carried out. Spectacles should be prescribed as appropriate, and treatment for amblyopia and strabismus carried
out as required.
+++ B
Regular hearing assessment, including otoscopy should be carried out on all children and adolescents with FVSD ++ B
Specific enquiry should be made about symptoms of urinary tract infection and enuresis. If present these should be
managed in the standard way
+++ B
Development should be assessed and enquiry should be made about school progress at each visit +++ B
Where developmental problems are identified a referral to a psychologist should be made so that appropriate
specialist advice can be given to schools
+++ B
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be detected in utero. The occurrence of occult neural
tube defects after VPA exposure in humans has not been
well documented in the literature but is seen in animal
models [95], therefore, checking for signs of occult le-
sions such as large (> 5 mm) sacral dimples or dermal si-
nuses is recommended. Small sacral dimples and pits
can be ignored[68]. A further associated malformation is
abdominal wall defect (omphalocele) [10, 12, 96], which
is obvious after birth and will need immediate surgical
intervention. Airway problems, principally stridor due to
laryngo or tracheomalacia, are increased in frequency
[10, 12, 39, 40] Infants with these problems should be
referred to a specialist in airway management for assess-
ment. Common minor malformations which may be
noted include overlapping or hypoplastic toes, especially
the fifth toes [12], minor differences in the ear shape
and postural talipes deformity [12, 53]. These usually be-
come less obvious over time and resolve with minor
intervention.
Following delivery, it is recommended that the mother
should have a chance to meet with an epilepsy specialist
nurse who will review her seizure management and pro-
vide practical advice on how mothers with epilepsy can
safely care for their baby once discharged home. At the
Table 5 Recommendations For The Management Of Fetal Valproate Spectrum Disorder (Continued)
Recommendation Agree
+++ > 75%
++ 51–74%
+ < 50%
Evidence
Strength
A B C
By virtue of having a mother with epilepsy children with FVSD may be at increased risk of seizures. If these occur
they should be managed in the standard way. Genetic testing for seizure predisposition genes should be
considered [62]
+++ B
Children with objective cognitive impairment should have an individualised educational plan or equivalent drawn
up and be offered tailored input with their education
+++ B
Educators of children with FVSD should be provided with information about the condition and about strategies to
best support affected individuals
++ B
Management of Adolescents With FVSD
The need for extra time or a scribe should be assessed when taking examinations ++ B
Health and social care service managers in children’s and adults’ services should work together in an integrated
way to ensure a smooth and gradual transition from paediatric to adult care and individuals with FVSD should be
involved in the transitional arrangements wherever possible.
+++ A
Annual assessment by an optometrist for refractive error is recommended +++ B
Management of Adults With FVSD
A designated general practitioner should be identified to coordinate care ++ B
An individualised educational plan should remain in place with annual reviews as long as it is necessary. In some
countries this is also allowable for adults
+++ B
An annual health check for medical problems in learning disabled patients should be carried out by the general
practitioner [81]
++ B
Weight should be monitored at the annual check and dietary advice given if overweight for height +++ B
Referral to a podiatrist should be undertaken where foot posture remains abnormal +++ B
An occupational therapy referral should be made so that an ergonomic assessment of the workplace or
educational setting should be carried out and adaptations made for any special needs
+++ B
Offer referral to a physiotherapist for fatigue management and advice on management of joint laxity and posture +++ B
Annual assessment by an optometrist for refractive error should be recommended +++ B
Anaesthetic Management Of The Individual with FVSD
Preoperative evaluation should include a full assessment of potential risk factors including a cardiological
assessment and ENT evaluation of the upper airway.
+++ B
Dysmorphic features such as micrognathia, small mouth and cleft palate should be assessed as they can alert the
anaesthetist to a potentially difficult airway and difficult endotracheal intubation
+++ B
Anaesthetists should have a high index of suspicion to subglottic narrowing and ENT presence may be required to
examine the lower airway in full.
+++ B
Postoperative care will require monitoring for apnoeas in neonates and infants. +++ B
A Supported by evidence from literature or full consensus
B Considered best practice in the area but lack of specific evidence
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time of discharge the first follow-up appointment with
the paediatrician should be arranged for the baby and
the local midwife and health visitor or equivalent should
be made aware of the need for extra surveillance.
Paediatric surveillance of the infant
It is recommended that children exposed to VPA in
utero should undergo a number of checks during child-
hood, timed to fit in with routine health checks and spe-
cific developmental stages. At each of these, growth,
development, hearing and vision should be checked and
any new problems identified, and referrals made to spe-
cialists as appropriate. In addition to the normal baby
health checks a paediatrician should review the baby at
6–8 weeks of age. This provides an opportunity to look
for any malformations which may have become apparent
since birth and check that the necessary screening inves-
tigations have been arranged. Some malformations such
as minor radial ray defects, for example, may have been
difficult to assess straight after birth. A referral can also
be made at this stage to an ophthalmologist so that
screening for ocular malformations, especially retinal
coloboma, can be carried out. This visit also provides an
opportunity to check for hip stability as the joint hyper-
mobility seen with FVSD [27] can be a contributing fac-
tor to congenital dislocation of the hip [14].
Pre-school surveillance
In addition to routine toddler health checks a review by
a paediatrician is recommended at eighteen months of
age as this is a key time for language assessment and
screening for symptoms of social communication dis-
order. Thereafter, annual health checks should be carried
out until school age by a community paediatrician or ap-
propriately trained specialist nurse with monitoring of
growth and enquiry about development, hearing and
eyesight problems being undertaken at each visit. These
visits provide an opportunity to check for symptoms
known to occur with increased frequency in FVSD. Evi-
dence of neurodevelopmental difficulties merits referral
for neuropsychological evaluation prior to or during the
first year of school to ensure adequate educational sup-
port and placement. It should be noted that children
may ‘grow into’ certain cognitive, social and develop-
mental deficits and for this reason a single follow up in
the infant years is not adequate [97].
School age surveillance
The aim of surveillance during the school years is to
make sure that any problems caused by VPA exposure
are recognised and managed appropriately during the
period of the child’s education, whilst not incurring too
much time off school for hospital appointments. This
ensures efficient use of healthcare resources, parents are
not excessively inconvenienced, and children are not
marked out as different or disadvantaged academically
because they need repeated days off school. The consen-
sus group therefore agreed on reviews taking place in
the school year prior to the move to high/secondary
school and the school year prior to taking public exami-
nations and making career choices. The age for these
might vary slightly from country to country. As with
other paediatric checks, enquiry about any medical
problems, hearing or eyesight problems, and difficulties
with school progress, behaviour and social interaction,
should be made, with referrals made to appropriate spe-
cialists (i.e. psychology or psychiatry) where necessary.
At 16–17 years, arrangements should be made for transi-
tion to adult care, the latter usually being undertaken by
the family doctor. At this point the doctor taking on an-
nual health checks should be provided with details of
past history and screening investigations, a summary of
any current concerns and a checklist such as the one in-
cluded as Additional file 3 outlining the ideal manage-
ment plan during adulthood.
Recommendations should be provided to schools
when required. Individuals with FVSD should be re-
ferred for a neuropsychological assessment, or for a
comprehensive cognitive assessment which includes, but
is not limited to, IQ, memory, language, executive and
attention abilities. This will allow recommendations to
the school and the family to be tailored., creating a more
bespoke intervention. As a minimum, a high proportion
of individuals with FVSD are likely to require additional
support in school around the learning of new informa-
tion and when children are required to take examina-
tions, an assessment should be made as to whether extra
time or a scribe is needed.
The risk of developmental delay after exposure to VPA
in utero has been reported to be in the region of 30%
[98–104], but the risk of adverse cognitive and other
neurodevelopmental outcomes is far greater when there
are physical signs of VPA embryopathy [27, 28]. Effects
on development have been seen in the absence of con-
genital malformations [58, 101]. They are dose-related
[103], so children exposed to higher doses of VPA are at
greater risk. In a Cochrane systematic review of neuro-
development [22], Bromley et al. concluded that there
was an average reduction of 9 points in the developmen-
tal quotient between children exposed to VPA and unex-
posed or control children, with the risk to school aged
IQ being a 7–11 point reduction in comparison to both
controls and other AED exposed children. Lowering of
group mean scores leads to an increase in the number of
children falling below the average range. For IQ, pro-
spective studies suggest that around 20–30% of individ-
uals with FVSD will demonstrate below average IQ;
however declines in ability are very much dose
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dependent [22]. In addition, further studies have shown
impairment of memory [37] and Erikkson et al. reported
more difficulty in remembering faces and learning lists
[101]. From a practical point of view, Adab et al. [98] in
a retrospective case control study demonstrated that
VPA exposed children had a 3.4 fold increased risk for
being assessed as having special educational needs and
the prospective study by Baker et al. [21] calculated that
this risk was even higher, ie around eight fold, if expos-
ure was to high dose VPA (defined as doses above 800
mg daily). Elkjaer et al. [104] found that a population of
Danish schoolchildren had lower grades in Danish and
maths if they had been exposed to VPA. The observa-
tions, overall, translate into a high number of VPA ex-
posed children requiring additional input with their
education, especially if exposed to doses of VPA greater
than 800 mg daily [105]. A recent population-based co-
hort study from Denmark by Christensen et al. [106]
suggested that there is a 48% increased risk of having
attention-deficit hyperactivity disorder (ADHD) after
prenatal exposure to VPA. In addition to the docu-
mented cognitive and academic difficulties, children with
FVSD may have problems with organisational and social
skills which impact on their school progress. Parents
have identified that training of educators including
teachers and teaching assistants to inform them about
the spectrum of difficulties seen in FVSD and strategies
which can be adopted at school to overcome these is of
significant benefit. As for all children with disabilities,
adjustments to classrooms or school buildings may also
be needed. In the UK this is covered under the Equality
Act 2010 and other countries have similar legislation.
Speech and language
Prospective studies of cognitive development in children
exposed to VPA during pregnancy have consistently
shown a clinically significant reduction in full scale IQ
compared to control populations, with greater impairment
of verbal IQ. Specific impairment of language skills has
also been documented [105] together with deficits in audi-
tory working memory [56, 105]. The most notable aspect
of the FVSD cognitive phenotype known to date is the fre-
quent discrepancy often seen between verbal and
non-verbal IQ, favouring non-verbal IQ [37, 56, 98]. There
is both prospective and retrospective evidence that chil-
dren with a history of VPA exposure are at risk of poorer
language development [27, 35, 57]. In view of these obser-
vations it is recommended that all VPA-exposed children
are carefully monitored for language delay. Those with
language deficits on a screening assessment at 18months
of age should be referred to a speech and language therap-
ist (SLT) for intervention if resources permit. Referral
should be made to the SLT by 2.5 years at the latest. When
decisions about school placements are made, it is
recommended that children with FVSD should be offered
a place at a school where staff have had speech and lan-
guage communication needs (SLCN) training. If specific
speech, language and communication needs have been
confirmed, then ideally child would be offered a place at a
specialist language unit attached to a mainstream school.
If this is not possible, then regular assessment/reviews of
progress and advice/intervention should be offered by a
qualified SLT as required.
Social communication disorder and autism Spectrum
disorder
The prevalence of autism spectrum disorder (ASD) mea-
sured in a UK population is around 1% [105]. Early case re-
ports had mentioned autism spectrum disorder in children
exposed to VPA. A prospective study carried out in Man-
chester reported an incidence of 6.3% for ASD in children
exposed to VPA monotherapy [25] and a Scottish
population-based study [24] reported an incidence of 8.9%
for ASD in an exposed group. Christiansen et al. [25]
undertook a population based study in Denmark of over
65,000 children born between 1996 and 2006 to see if ASD
was significantly increased after VPA exposure. The study
identified a doubling of risk for childhood autism in the
432 VPA exposed children. Wood et al. reported their find-
ings of a prospective evaluation of autistic traits [107].
When screening for ASD traits, the incidence of ASD was
7.7% in a group exposed to VPA monotherapy and 46.7%
in those where VPA was used as polytherapy; although the
group size was small. Risk of autistic spectrum disorder and
social difficulties has been demonstrated to increase with
increasing dose of VPA. This also ties in with the observa-
tion of an ASD-like phenotype in rodents exposed to VPA
during pregnancy [107]. Clinical experience backs up the
finding of Wood et al. that there are a significant number
of individuals with FVSD that may not meet diagnostic cri-
teria for an autistic spectrum disorder but have significant
difficulties with social communication. Given that there are
now early intervention programmes for ASD [108, 109],
screening and formal assessment for this is warranted so
that symptoms can be detected early, appropriate help can
be put in place, and a diagnosis of ASD can be factored in
when planning school placements.
Growth and general health
Birthweight in VPA exposed children does not differ
from that of control or unexposed children [8, 14, 27,
52]. There is little data on growth as few long term
follow-up studies have studied this, but unpublished data
from follow up of the Liverpool and Manchester Pro-
spective cohort presented by Mawer et.al. [52] which in-
cluded 57 infants exposed to VPA monotherapy and 283
controls has not identified any significant differences in
height, weight or head circumference at the age of 6
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years. As regards older individuals with FVSD, the con-
sensus group made the personal observations that
weight may increase from the time of puberty so this
should continue to be monitored and dietary and life-
style advice given where needed. There are some reports
of early puberty but this has not been formally studied.
It should be noted that although a number of medical
problems have been reported in VPA exposed children
[27], for the most part their management is no different to
that of other children with the same complaints. In a large
population based study, the rates of GP contact were in-
creased for valproate exposed children but the increase
was small [110]. Consistently, in the Liverpool/Manchester
cohort [52], 20/57 (35%) of the VPA monotherapy patients,
and 12/26 (46%) exposed to VPA as polytherapy, had
needed to consult a doctor for a medical problem com-
pared to 65/283 (23%) controls (unpublished data). Similar
types of problem were encountered in both groups and in-
cluded asthma, eczema, upper respiratory tract infections
and otitis media. Moore et al. [27] reported the presence of
otitis media in 19/57 children with AED exposure, 15 of
whom were exposed to VPA monotherapy (44%). This was
a somewhat biased group, ascertained through a Fetal
Anticonvulsant Support group, and caution is required in
interpreting these findings. In the Liverpool/Manchester
prospective case controlled cohort study [52] the incidence
of hearing problems and otitis media did not differ be-
tween case and control cohorts (unpublished data). In fact
80% of otherwise healthy children experience otitis media
before 10 years of age and 40% of 2 year olds [111] and
therefore this was not deemed to be a specific symptom of
FVSD by the consensus group. However, it could be
hypothesised that the increased incidence of cleft palate, a
risk factor for conductive hearing loss, together with subtle
differences in structure of the mid face and skull, may
make some within the FVSD population slightly more sus-
ceptible to recurrent episodes of otitis media. One older
individual with FVS has required treatment for a cholestea-
toma (personal communication regarding patient in cohort
reported by Mohd Yunos et al. [112]. Surveillance for otitis
media, to include otoscopy at each clinic visit seems pru-
dent as it would be important that risk of conductive hear-
ing loss is minimised in a child who may have other
disabilities. The occurrence of hyperacusis has been re-
ported frequently in VPA children by parents but has not
been studied formally. It can, however, pose problems in
noisy environments, including schools. Delayed toilet train-
ing and enuresis have been reported. In the Liverpool/
Manchester study referred to above, 12/196 (6.1%) com-
pleting a health questionnaire at 6 years had functional
bladder problems but so did 14/256 (5.4%) of the control
cohort (unpublished data). In this same cohort 11/196
(5.6%) had a GU malformation diagnosed by the age of 6
years compared to an incidence for similar malformations
of only 5/256 (1.9%) in controls. As there is an increased
risk for structural GU malformations, a one-off scan of the
kidneys and urinary tract is recommended after infancy. If
present, renal anomalies will require management as for
any child with similar malformations and prophylactic an-
tibiotics or surgery may be needed. In later childhood and
adolescents, enquiry regarding enuresis and urinary prob-
lems should be made with referral to appropriate special-
ists. There have been no specific studies of this problem in
FVSD, but there are several anecdotal reports of impaired
bladder sensation and enuresis affecting social activities e.g.
participation in school residential trips and clinical experi-
ence within the consensus group suggested that functional
problems of this type appear to be more common in
FVSD. The majority of children with FVSD are, by virtue
of having a parent with a seizure disorder, at higher risk of
having seizures themselves. Seizures do not appear to be a
consistent feature of VPA exposure per se, and have rarely
been documented in reports, but the seizure risk would be
increased if a mother passes on a dominant seizure predis-
posing genetic variant to a child [62]. In cases of familial
epilepsy, consideration should be given to screening for
underlying genetic variants in seizure predisposing genes.
Some of these variants might also have an impact on intel-
lectual development [113].
Ocular anomalies
Glover et al. [47] documented the ocular findings in 27
individuals exposed to valproate monotherapy. 50% had
myopia of > − 1 dioptre and in 28.6% the refractive error
was greater than − 4 dioptres. 11% of valproate exposed
children had anisometropia and strabismus was com-
mon. Myopia had gone undetected or untreated in a sig-
nificant proportion of cases. Shah et al. [48] and Jackson
et al. [49] both reported the occurrence of coloboma in
valproate exposed infants. A blocked or absent lacrimal
tear duct may also occur at increased frequency (Turn-
penny, personal communication). In view of the occur-
rence of both congenital malformations which might
impact on vision and the high risk of development of a
significant refractive error, we have made recommenda-
tions for both an early ophthalmological assessment and
ongoing surveillance for refractive error.
Joint hypermobility
In the case series reported by Moore et al. [27] joint hy-
permobility was a prominent feature in the VPA-exposed
children. It had been documented in 24/34 valproate
monotherapy patients and 10/12 VPA polytherapy pa-
tients. In addition hernia was present in 4 of these. The
finding of joint hypermobility in VPA exposed children
has been reported frequently by others [12, 39, 40] with
hypotonia also described as a feature in many cases. If
present it should be managed in the standard way. A
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Beighton score [79] should be measured at the school age
clinic visits and if the score is greater than 6 a referral to a
paediatric physiotherapist should be made and an age ap-
propriate graded exercise programme administered to
build up core muscle strength and endurance. Good pos-
ture and spinal strengthening exercises are recommended.
Exercises might also include swimming and soft play. Spe-
cial requirements for joint hypermobility should be in-
cluded in the formal education plan for the children.
Hypermobility can manifest as leg pain if weight bearing
when walking tends to be on the insides of the feet, and a
referral for orthotics should be made. Joint hypermobility
can cause problems at school in covering longer distances
between classrooms and stairs, and in holding a pen to
write for long periods. An ergonomic assessment of the
school environment by an occupational therapist should
be undertaken to highlight problem areas in those cases
where there are significant problems. Joint hypermobility
can also present as chronic fatigue in children and adults
and, again, referral to the physiotherapist is recommended
for management.
Other skeletal manifestations
Many of the skeletal abnormalities seen with VPA expos-
ure are minor and do not require treatment. These in-
clude postural talipes, and overlapping or hypoplastic toes
[6, 12, 39, 51, 114]. More significant limb defects, princi-
pally radial ray defects, tend to occur in those exposed to
higher doses of VPA. These can vary in severity, but even
mild defects can cause some functional impairment, e.g.
with writing. It is important, therefore, to look for minor
signs such as flattening of the thenar eminence and check
function, with referral to an occupational therapist or
hand surgeon if there are significant problems. Talipes
which is structural or does not respond to conservative
treatment should be managed by a specialist surgeon.
Where talipes is resistant to treatment, where there is a
sacral dermal sinus or a large or deep dimple, or where
there are abnormal neurological signs in the lower limbs,
imaging of the spine is recommended [69, 75].
Adults with fetal valproate Spectrum disorder
Few large studies have been carried out on adolescents
and adults with FVSD, and much of the information is
limited to anecdotal reports, clinical experience and un-
published data. Bromley et al. have studied intellectual
functioning in 18 individuals over the age of 16 with a
confirmed diagnosis of FVS [26] and identified increased
rates of intellectual disability (IQ < 70), with poor verbal
comprehension and reasoning, impaired auditory working
memory and processing speed deficits, providing evidence
that the neurodevelopmental deficits are persistent into
adulthood. Information gathered from individual families
support the fact that difficulties continue into adult life,
affecting independence and employment opportunities as
well as mental health and ability to form relationships.
However, it has not been possible to compare incidences
with normal population controls. At the present time
there does not appear to be an increased incidence of any
specific adult medical disorders, though long term effects
of congenital malformations and sequelae of joint hyper-
mobility can remain problematic. Weight increase, as
noted above, may be an associated feature but has not yet
been studied formally. In most cases the family doctor or
general practitioner will be the person responsible for care
of adults who were exposed to VPA in utero. In some
countries there is national guidance for carrying out an-
nual health checks on adults with learning disability [81]
and the checklist (Additional file 3) summarises the points
which need to be addressed specifically by the GP in older
patients with FVSD.
Transition to adult care
Parents identified the stage of transition to adult care
between the ages of 16 and 20 as a particularly problem-
atic time. In many countries plans for special educa-
tional needs can continue through school into college
and University and thus they can continue to be of
benefit. Moving to a suitable college may require travel-
ling further each day and this might pose logistical is-
sues, especially if individuals’ cognitive organisational
skills are affected, and it could also incur extra costs.
These issues are of great importance to families and
should be addressed at the time of transition. Transfer
of medical care from the paediatrician to the family doc-
tor occurs in the transitional period and family doctors
need to be provided with clear and consistent informa-
tion as to what health surveillance adults will need as
many will be unfamiliar with FVSD.
Recommendations for the management of FVSD
The recommendations for management of FVSD are
given in Table 5. Short versions of these recommenda-
tions, tailored to specific groups are included as Add-
itional files 1, 2, 3, 4 and 5.
Facilitators and barriers to application of the
consensus recommendations
This consensus document was drawn up by an expert
group covering several different European member
states, and reviewing the world-wide literature. The aim
is that it will be used in different countries where it is
likely that there will be differing access to health care,
and different provision of support for development and
education. When drawing up the recommendations we
had to take this into account and in some areas this
meant we needed to be less specific and more general in
our recommendations as a result. To overcome this
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barrier it may be possible in the future to produce ver-
sions of the care plan which do not differ in their core
recommendations but provide additional information
tailored to a specific healthcare system or country, trans-
lating the documents into the language required.
The consensus document is a lengthy one and many
parents and professionals with busy clinical or other
commitments may prefer a short summary. The group
felt strongly that shorter summary documents, tailored
to different target groups, should be prepared alongside
the full consensus paper. This was also favoured by the
parent groups. We thus produced one-page summary
sheets specifically for parents, the paediatric team, gen-
eral practitioners who will be overseeing adult care and
teachers. These are appended as Additional files 1, 2, 3
and 4. We have put references or links in the documents
to existing resources which will be of help to those
implementing the consensus recommendations, for ex-
ample to templates used by general practitioners to
undertake an adult learning disability health check [12],
and information on how to assess joint hypermobility
using the Beighton score [79].
Resource implications of the recommendations
Though adverse effects of VPA exposure were first de-
scribed in the literature in the 1980s, recognition of VPA
teratogenic effects has taken time [115], especially as
there is no diagnostic biomarker for FVSD and, where
development is concerned, there are many confounding
factors which could be contributing to developmental
problems including other drug exposures, seizures dur-
ing pregnancy, and unknown genetic factors. The
spectrum of problems caused by exposure to VPA in
pregnancy was not specifically acknowledged as an entity
until the results of larger prospective studies started to
become available, and this has meant that few individ-
uals with this condition have had any coordinated man-
agement in the past. Implementing a new health and
developmental surveillance system for this group will
therefore, most likely have resource implications. We
know, however, from the studies by Adab [98] and Baker
[21], that a large proportion of children are receiving
additional educational input already, so these costs may
not increase unduly. There is no specific drug treatment
for the disorder, so we do not anticipate that use of spe-
cific drugs will increase dramatically as a result of our
recommendations, although methylphenidate may be
prescribed with increased frequency if ADHD is recog-
nised more frequently [106]. Where resource implica-
tions will have most impact is in the need for
monitoring of development and for neuropsychological
assessments throughout childhood and early adulthood,
interventions which were not previously always carried
out. These are offset by the fact that if children with
FVSD are provided with the right sort of support they
may do better developmentally, behaviourally and so-
cially, and thus pose less of an economic cost to society
later on. The very firm guidance on avoidance of VPA
treatment during pregnancy published by the EMA in
2018 [2] will most likely lead to a continuing drop in the
number of children with FVSD, and we anticipate that it
will become a very rare occurrence in the future. Thus,
whilst we consider it important for the cohort of existing
individuals to have high quality care as outlined in the
recommendations, we hope and accept that the need for
these will decline as the years go by.
Evaluating how the recommendations within this care
plan are being applied will encourage good practice and
will also have potential to provide important feedback
which will be used to improve patient care. We have thus
tried to formulate our recommendations in such a way
that they can be used as standards for audit, e.g. phrasing
these as “a developmental assessment using a validated
tool should be carried out between 6 and 12 months”. We
aimed to have criteria that could be used across different
countries, accepting that there will need to be some modi-
fications. We aim to undertake a first audit using these
criteria 12months after their publication.
Development of these recommendations drew on the
existing work carried out by Dr. Hubert Journel and Pro-
fessor Sylvie Odent in production of the French PNDS
document [30] funded by the French government and on
the existing research undertaken in the field by several of
the experts concerned. The work on the consensus
document was independent of this previous research,
though drew on findings from it. The work of the
group was facilitated through the European Reference
Network ERN-ITHACA which is funded by a CHA-
FEA grant 769,045. Administrative support and re-
sources for the consensus working group meeting
were provided from this grant. No specific funding
has been received from industry or other sources. All
contributing working group members were asked to
declare any possible conflicts of interest.
Conclusions
These recommendations provide a framework for the
diagnosis and management of FVSD. In view of the mul-
tisystem involvement it is important that a lead clinician
is identified to coordinate care. This is likely to be a
community paediatrician during the childhood years but
general practitioners/family doctors will have an increas-
ing role to play as this cohort of exposed individuals
reach adulthood. These recommendations aim to be
pragmatic so that they can be followed in different
healthcare systems but it is likely that there will be dif-
ferences in provision of care between different countries
which will need to be taken into consideration. As many
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of the individuals concerned are currently not having
any health surveillance, implementing these recommen-
dations may incur some costs, yet we believe that good
quality care will overall improve quality of life, prevent
complications and enable affected individuals to achieve
their full potential, thus ultimately benefiting themselves
and society as a whole. The recommendations will be
updated on a two-yearly basis by consensus conference
between members of the working group.
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